| Karen A Stice, ARNP | |
|
4003 Kresge Way, Ste 312, Louisville, KY 40207 | |
| (502) 899-7377 | |
| (502) 899-1972 |
| Full Name | Karen A Stice |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 4003 Kresge Way, Louisville, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376517227 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 2579P (Kentucky) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 2579P (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen A Stice, ARNP 4003 Kresge Way, Ste 312, Louisville, KY 40207 Ph: (502) 899-7377 | Karen A Stice, ARNP 4003 Kresge Way, Ste 312, Louisville, KY 40207 Ph: (502) 899-7377 |
News Archive
Surprising new scientific research is raising concerns about the potential health and environmental hazards of tungsten - a metal used in products ranging from bullets to light bulbs to jewelry - that scientists once thought was environmentally-benign, according to an article scheduled for the Jan. 19 issue of Chemical & Engineering News , ACS' weekly newsmagazine.
Hysterectomy and oophorectomy (the removal of ovaries) are performed to treat various diseases in women, including cancer. These procedures are accompanied not only by a decline in estrogen but also testosterone levels in the blood.
After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.
A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.
› Verified 3 days ago